{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:26:32Z","timestamp":1769084792765,"version":"3.49.0"},"reference-count":33,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fresenius Kabi SwissBioSim GmbH","award":["2020-004422-31"],"award-info":[{"award-number":["2020-004422-31"]}]},{"name":"Fresenius Kabi SwissBioSim GmbH","award":["NCT04934072"],"award-info":[{"award-number":["NCT04934072"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To demonstrate therapeutic equivalence of the proposed denosumab biosimilar FKS518 to the originator denosumab (US-licensed Prolia\u00ae, reference product), a potent antiresorptive biologic that increases bone mineral density (BMD) and reduces the risk of fractures, in women with postmenopausal osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This 78-week double-blind, controlled, randomized, multicenter, multiple-dose, 2-arm, parallel-group study compared the efficacy (BMD), pharmacodynamic (bone biomarkers), safety, tolerability, and immunogenicity profiles of FKS518 with those of reference denosumab in women with postmenopausal osteoporosis. Primary\u2014percentage change from baseline to 52 weeks in lumbar spine BMD and area under the effect curve from baseline to week 26 of serum C-terminal cross-linking telopeptide of type 1 collagen\u2014and secondary results from the 52-week core treatment period are reported here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Postmenopausal women with osteoporosis were randomized to receive 60\u2005mg of FKS518 (n = 277) or reference denosumab (n = 276) every 26 weeks. Demographics, baseline characteristics and medical history were similar between treatment groups. Therapeutic equivalence of FKS518 and reference denosumab was demonstrated for efficacy and pharmacodynamic characteristics. All sensitivity analyses, supportive estimands, secondary efficacy, and pharmacodynamic endpoint analyses consistently showed similarity between the 2 products. Safety outcomes were consistent with the known safety profile of denosumab and were comparable between FKS518 and reference denosumab. Immunogenicity was infrequently observed and similar between the FKS518 and the reference denosumab groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated therapeutic equivalence of, and comparable pharmacokinetics, safety, and immunogenicity profiles between FKS518 and reference denosumab, completing the clinical evidence to propose FKS518 as a biosimilar to denosumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf164","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:25:42Z","timestamp":1761045942000},"source":"Crossref","is-referenced-by-count":1,"title":["LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis"],"prefix":"10.1210","volume":"9","author":[{"given":"Ewa","family":"Krecipro-Nizinska","sequence":"first","affiliation":[{"name":"Centrum Medyczne FutureMeds Wroclaw , Wroc\u0142aw 53-673 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Pluskiewicz","sequence":"additional","affiliation":[{"name":"Department and Clinic of Internal Diseases, Diabetology and Nephrology, Metabolic Bone Diseases Unit, Faculty of Medical Sciences in Zabrze, Medical University of Silesia , Katowice 41-800 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Supronik","sequence":"additional","affiliation":[{"name":"ZDROWIE Osteo-Medic s.c., L. i-A. Racewicz, A. i J. Supronik , Bia\u0142ystok 15-351 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Szeles","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Fresenius Kabi SwissBioSim , CH-1262 Eysins ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0289-6556","authenticated-orcid":false,"given":"Corinne","family":"Petit-Frere","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Fresenius Kabi SwissBioSim , CH-1262 Eysins ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Varone","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Fresenius Kabi SwissBioSim , CH-1262 Eysins ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-4417","authenticated-orcid":false,"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Division of Bone Diseases, Geneva University Hospital and Faculty of Medicine, University of Geneva , CH-1211 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Valter","sequence":"additional","affiliation":[{"name":"Nordestmedical Center, Center for Clinical and Basic Research AS , Tallinn 10128 ,","place":["Estonia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2025112712014272700_bvaf164-B1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jama.2025.6003","article-title":"Osteoporosis: a review","volume":"334","author":"Morin","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"2025112712014272700_bvaf164-B2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11914-019-00536-8","article-title":"Bone health in men with prostate cancer: review article","volume":"17","author":"El Badri","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"2025112712014272700_bvaf164-B3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fimmu.2019.00629","article-title":"The RANKL\u2013RANK axis: a bone to thymus round trip","volume":"10","author":"Sobacchi","year":"2019","journal-title":"Front Immunol"},{"key":"2025112712014272700_bvaf164-B4","author":"Amgen"},{"key":"2025112712014272700_bvaf164-B5","author":"Amgen"},{"issue":"6","key":"2025112712014272700_bvaf164-B6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000371845","article-title":"The RANKL\u2013RANK story","volume":"61","author":"Nagy","year":"2015","journal-title":"Gerontology"},{"issue":"1","key":"2025112712014272700_bvaf164-B7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"2025112712014272700_bvaf164-B8","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux","year":"2022","journal-title":"J Bone Oncol"},{"issue":"1","key":"2025112712014272700_bvaf164-B9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11657-023-01211-3","article-title":"The clinical effectiveness of denosumab (Prolia\u00ae) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis","volume":"18","author":"Nicolopoulos","year":"2023","journal-title":"Arch Osteoporos"},{"issue":"2","key":"2025112712014272700_bvaf164-B10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025112712014272700_bvaf164-B11","doi-asserted-by":"crossref","first-page":"17455057221149493","DOI":"10.1177\/17455057221149493","article-title":"Review of bone health in women with estrogen receptor-positive breast cancer receiving endocrine therapy","volume":"19","author":"Malagrin\u00f2","year":"2023","journal-title":"Womens Health (Lond)"},{"key":"2025112712014272700_bvaf164-B12","author":"Amgen"},{"key":"2025112712014272700_bvaf164-B13","author":"Amgen"},{"issue":"6","key":"2025112712014272700_bvaf164-B14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00198-020-05769-3","article-title":"Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women","volume":"32","author":"Tran","year":"2021","journal-title":"Osteoporos Int"},{"key":"2025112712014272700_bvaf164-B15","first-page":"154","article-title":"Economic burden of osteoporosis in the world: a systematic review","volume":"34","author":"Rashki Kemmak","year":"2020","journal-title":"Med J Islam Repub Iran"},{"issue":"10","key":"2025112712014272700_bvaf164-B16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/jbmr.4713","article-title":"Economic costs of severe osteoporotic fractures continue to increase at expense of refracture","volume":"37","author":"Clarke","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025112712014272700_bvaf164-B17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/biom9090410","article-title":"The breakthrough of biosimilars: a twist in the narrative of biological therapy","volume":"9","author":"Kabir","year":"2019","journal-title":"Biomolecules"},{"issue":"4","key":"2025112712014272700_bvaf164-B18","first-page":"3","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"},{"key":"2025112712014272700_bvaf164-B19","author":"European Commission"},{"key":"2025112712014272700_bvaf164-B20","doi-asserted-by":"crossref","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2025112712014272700_bvaf164-B21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clinthera.2011.12.005","article-title":"Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States","volume":"34","author":"Ahmed","year":"2012","journal-title":"Clin Ther"},{"key":"2025112712014272700_bvaf164-B22","author":"U.S. Department of Health and Human Services"},{"key":"2025112712014272700_bvaf164-B23","author":"U.S. Department of Health and Human Services"},{"key":"2025112712014272700_bvaf164-B24","author":"U.S. Department of Health and Human Services"},{"key":"2025112712014272700_bvaf164-B25","author":"European Medicines Agency"},{"issue":"16_suppl","key":"2025112712014272700_bvaf164-B26","doi-asserted-by":"crossref","first-page":"e15097","DOI":"10.1200\/JCO.2024.42.16_suppl.e15097","article-title":"A double-blind, randomized, two-arm, single-dose, parallel-group study in healthy participants to compare the pharmacokinetics, pharmacodynamics, and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator (LUMIADE-1 study)","volume":"42","author":"Sadek","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025112712014272700_bvaf164-B27","article-title":"Supplemental Data for \u201cLUMIADE 3: therapeutic equivalence of denosumab biosimilar FKS518 to reference product in postmenopausal osteoporosis\u201d","author":"Krecipro-Nizinska","year":"2025","journal-title":"OSF"},{"key":"2025112712014272700_bvaf164-B28","doi-asserted-by":"crossref","first-page":"1759720X19883973","DOI":"10.1177\/1759720X19883973","article-title":"Balancing benefits and risks in the era of biologics","volume":"11","author":"Adami","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"2025112712014272700_bvaf164-B29","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","article-title":"International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis","volume":"49","author":"Vasikaran","year":"2011","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"2025112712014272700_bvaf164-B30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"2025112712014272700_bvaf164-B31","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025112712014272700_bvaf164-B32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025112712014272700_bvaf164-B33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","article-title":"Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study","volume":"16","author":"Bolognese","year":"2013","journal-title":"J Clin Densitom"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf164\/64831908\/bvaf164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/12\/bvaf164\/64831908\/bvaf164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/12\/bvaf164\/64831908\/bvaf164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:01:51Z","timestamp":1764262911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf164\/8294385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf164","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,22]]},"article-number":"bvaf164"}}